Laura Olivari

Laura Olivari

Auto-generated profile, based on publicly available information

Laura Olivari

Nuclear Medicine Unit, IRCCS Ospedale Sacro Cuore Don Calabria, 37024 Negrar, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2023 in Life
Verified
Journal Article
Open access
PDF file
PGPriscilla Guglielmo
Priscilla Guglielmo
Pierpaolo AlongiPierpaolo Alongi
Pierpaolo Alongi
LBLucia Baratto
Lucia Baratto
EAElisabetta Abenavoli
Elisabetta Abenavoli
ABAmbra Buschiazzo
Ambra Buschiazzo
Laura EvangelistaLaura Evangelista
Laura Evangelista
FAPI-based radiopharmaceuticals are a novel class of tracers, mainly used for PET imaging, which have demonstrated several advantages over [18F]FDG, especially in the case of low-grade or well-differentiated tumors. We conducted this systematic review to evaluate all the studies where a head-to-head comparison had been performed to explore the potential utility of FAPI tracers in clinical practice. FAPI-based radiopharmaceuticals have shown promising results globally, in particular in detecting peritoneal carcinomatosis, but studies with wider populations are needed to better understand all the advantages of these new radiopharmaceuticals.

19 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
PGPriscilla Guglielmo
Priscilla Guglielmo
Pierpaolo AlongiPierpaolo Alongi
Pierpaolo Alongi
LBLucia Baratto
Lucia Baratto
MCMiriam Conte
Miriam Conte
EAElisabetta Abenavoli
Elisabetta Abenavoli
Laura EvangelistaLaura Evangelista
Laura Evangelista
(1) Background: Thyroid cancer (TC) is often treated with surgery followed by iodine-131. Up to 50% of the instances of TC lose their avidity to 131I, becoming more aggressive. In this scenario, [18F]FDG PET/CT imaging is used for evaluating the widespread nature of the disease, despite its low sensitivity and a false negative rate of 8–21.1%. A novel class of PET agents targeting the fibroblast activation protein inhibitor (FAPi) has emerged, studied particularly for their potential application to theranostics. (2) Methods: A search of the literature was performed by two independent authors (P.G. and L.E.) using the PubMed, Scopus, Web of Science, Cochrane Library, and EMBASE databases. The following terms were used: “FAP” or “FAPi” or “Fibroblast activating protein” and “thyroid” or “thyroid cancer”, in different combinations. The included papers were original articles, clinical studies, and case reports in the English language. No time limits were used. Editorials, conference papers, reviews, and preclinical studies were excluded. (3) Results: There were 31 papers that were selected. Some studies reported a low or absent FAPi uptake in TC lesions; others reported promising findings for the detection of metastases. (4) Conclusions: The preliminary results are encouraging. FAPI agents are an alternative to [18F]FDG and a promising theranostic tool. However, further studies with a larger population are needed.

4 June 2020 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
LOLaura Olivari
Laura Olivari
NRNiccolo Riccardi
Niccolo Riccardi
PRPaola Rodari
Paola Rodari
AAAndrea Angheben
Andrea Angheben
PAPaolo Artioli
Paolo Artioli
MSMatteo Salgarello
Matteo Salgarello

17 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
EPEdoardo Pastorello
Edoardo Pastorello
Luca NicosiaLuca Nicosia
Luca Nicosia
Francesco CucciaFrancesco Cuccia
Francesco Cuccia
LOLaura Olivari
Laura Olivari
MFMatilde Fiorini
Matilde Fiorini
Filippo AlongiFilippo Alongi
Filippo Alongi
Background and purpose: Stereotactic body radiotherapy (SBRT) has a consolidated role in the treatment of bone oligometastases from prostate cancer (PCa). While the evidence for spinal oligometastases SBRT was robust, its role in non-spinal-bone metastases (NSBM) is not standardized. In fact, there was no clear consensus about dose and target definition in this setting. The aim of our study was to evaluate efficacy, toxicity, and the pattern of relapse in SBRT delivered to NSBM from PCa. Materials and methods: From 2016 to 2021, we treated a series of oligo-NSBM from PCa with 68Ga-PSMA PET/CT-guided SBRT. The primary endpoint was local progression-free survival (LPFS). The secondary endpoints were toxicity, the pattern of intraosseous relapse, distant progression-free survival (DPFS), polimetastases-free survival (PMFS), and overall survival (OS). Results: a total of 150 NSBM in 95 patients were treated with 30–35 Gy in five fractions. With a median follow-up of 26 months, 1- and 3 years LPFS was 96.3% and 89%, respectively. A biologically effective dose (BED) ≥ 198 Gy was correlated with improved LPFS (p = 0.007). Intraosseous relapse occurred in eight (5.3%) cases. Oligorecurrent disease was associated with a better PMFS compared to de novo oligometastatic disease (p = 0.001) and oligoprogressive patients (p = 0.007). No grade ≥ 3 toxicity occurred. Conclusion: SBRT is a safe and effective tool for NSBM from PCa in the oligometastatic setting. Intraosseous relapse was a relatively rare event. Predictive factors of the improved outcomes were defined.

24 September 2020 in Clinical and Translational Imaging
Verified
Journal Article
Closed access
PDF file
LOLaura Olivari
Laura Olivari
NRNiccolò Riccardi
Niccolò Riccardi
PRPaola Rodari
Paola Rodari
DBDora Buonfrate
Dora Buonfrate
SDStefania Diodato
Stefania Diodato
MSMatteo Salgarello
Matteo Salgarello